Biodexa Pharmaceuticals Plc (BDRX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Biodexa Pharmaceuticals Plc (BDRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $544,662, listed on NASDAQ, employing roughly 11 people, carrying a beta of 1.19 to the broader market. Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Led by Stephen Anthony Stamp, public since 2015-12-07.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for BDRX as of 2026-09-22; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.